0
The penetration of biosimilars in Europe varies widely between countries and therapy areas [1].
- Home
-
Generics
News
- FDA approves generic teriparatide and levetiracetam
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
Research
- Japan’s drug shortage crisis: challenges and policy solutions
- Saudi FDA drug approvals and GMP inspections: trend analysis
- Generic medications in the Lebanese community: understanding and public perception
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
-
Biosimilars
News
- FDA approves biosimilars: ustekinumab Otulfi and eculizumab Epysqli
- EMA recommends approval of aflibercept biosimilars Afqlir and Opuviz
- FDA approves second strength of trastuzumab biosimilar Hercessi
- FDA approves aflibercept biosimilars Enzeevu and Pavblu
Research
- Long-term real-world safety experience of biosimilars confirms concept of biosimilarity
- Budget impact analysis of Rixathon introduction in Chile for non-Hodgkin lymphoma
- Biosimilars in inflammatory bowel disease: are we ready for multiple switches
- Topline results from clinical development programme for candidate biosimilar AVT05 golimumab
- MORE EDITORIAL SECTIONS
- Search
Post your comment